Total Funding
27
50
Total FundingSeed raised
Growth Score
-4 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
111822
Da Zen Theranostics develop a product that can target cancer cells, function as a contrast agent to improve the visibility of cancer cells.
Leland W.K. Chung: Founder
About the Company
Da Zen Theranostics develop a product that can target cancer cells, function as a contrast agent to improve the visibility of cancer cells. It functions as a contrast agent to improve the visibility of cancer cells during diagnostic imaging and deliver a therapeutic drug to destroy cancerous cells. The product will be based on a chemical compound
that was created by Dr. Maged Henary, associate professor of chemistry at Georgia State. Henary’s chemical compound, a heptamethine cyanine also known to the scientific community as MHI-148, is already being used internationally in cancer imaging research.
The company was founded in 2017 and is based in San Jose, California.
